Owkin is entering a new partnership with AstraZeneca to develop a gBRCA pre-screening solution in breast cancer directly from digitised pathology slides

David Dellamonica shared a post by Jean-Frederic Petit-Nivard, Chief Commercial Officer at Owkin, on LinkedIn, adding:

“Incredibly proud of this strategic partnership.
Huge congratulations to Thomas Di Maio and all the team involved in this new venture !”

Quoting Jean-Frederic Petit-Nivard:

“Exciting News!
Owkin is delighted to enter into a new partnership with AstraZeneca to develop a gBRCA pre-screening solution, an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitised pathology slides.

The goal of the collaboration is to develop accessible and robust diagnostic solutions to help patients get optimal care.”

Source: David Dellamonica/LinkedIn and Jean-Frederic Petit-Nivard/LinkedIn

David Dellamonica is the Global Head of Precision Digital Healthcare at AstraZeneca. He leads the Precision Digital Health Delivery team, driving initiatives across all AstraZeneca business units and implementing digital solutions throughout the care pathway. He has authored publications on AI, oncology, cardio-metabolic care pathways, and value-based partnerships. Dellamonica also actively contributes to discussions on the European Commission’s Data Strategy and AI White Paper.